Overcoming the Risk-Treatment Paradox: Prescribing GDMT for Severe Heart Failure.
Publication
, Journal Article
Greene, SJ; Kittipibul, V; Dunlay, SM
Published in: JACC Heart Fail
April 2025
Duke Scholars
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
April 2025
Volume
13
Issue
4
Start / End Page
628 / 630
Location
United States
Related Subject Headings
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Greene, S. J., Kittipibul, V., & Dunlay, S. M. (2025). Overcoming the Risk-Treatment Paradox: Prescribing GDMT for Severe Heart Failure. JACC Heart Fail, 13(4), 628–630. https://doi.org/10.1016/j.jchf.2025.01.014
Greene, Stephen J., Veraprapas Kittipibul, and Shannon M. Dunlay. “Overcoming the Risk-Treatment Paradox: Prescribing GDMT for Severe Heart Failure.” JACC Heart Fail 13, no. 4 (April 2025): 628–30. https://doi.org/10.1016/j.jchf.2025.01.014.
Greene SJ, Kittipibul V, Dunlay SM. Overcoming the Risk-Treatment Paradox: Prescribing GDMT for Severe Heart Failure. JACC Heart Fail. 2025 Apr;13(4):628–30.
Greene, Stephen J., et al. “Overcoming the Risk-Treatment Paradox: Prescribing GDMT for Severe Heart Failure.” JACC Heart Fail, vol. 13, no. 4, Apr. 2025, pp. 628–30. Pubmed, doi:10.1016/j.jchf.2025.01.014.
Greene SJ, Kittipibul V, Dunlay SM. Overcoming the Risk-Treatment Paradox: Prescribing GDMT for Severe Heart Failure. JACC Heart Fail. 2025 Apr;13(4):628–630.
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
April 2025
Volume
13
Issue
4
Start / End Page
628 / 630
Location
United States
Related Subject Headings
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology